Transcriptomics

Dataset Information

0

Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer


ABSTRACT: PURPOSE: To develop a predictive test for response and survival following neoadjuvant taxane-anthracycline chemotherapy for HER2-negative invasive breast cancer. METHODS: We developed a microarray-based gene expression test from pre-treatment tumor biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status,pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Tumors were classified as treatment-sensitive if predicted to have pathologic response (and not resistance) to chemotherapy, or sensitive to endocrine therapy. We tested predictive accuracy, with 95% confidence interval (CI), for pathologic response (PPV, positive predictive value), distant relapse-free survival (DRFS), and absolute risk reduction at median follow-up in 198 other patients. Independence from clinical-pathologic factors was assessed in a multivariate Cox regression analysis based on the likelihood ratio test. Other evaluable, published response predictors (genomic grade index (GGI), intrinsic subtype (PAM50), pCR predictor (DLDA30)) were compared.

ORGANISM(S): Homo sapiens

PROVIDER: GSE25065 | GEO | 2011/05/11

SECONDARY ACCESSION(S): PRJNA142731

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2011-05-11 | GSE25055 | GEO
2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress
2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress
2009-07-09 | E-GEOD-16391 | biostudies-arrayexpress
2015-01-21 | E-GEOD-48073 | biostudies-arrayexpress
2015-01-21 | GSE48073 | GEO
2009-07-09 | GSE16391 | GEO
2012-05-11 | E-GEOD-37946 | biostudies-arrayexpress
2014-02-01 | E-TABM-1186 | biostudies-arrayexpress
2024-01-25 | GSE240535 | GEO